|
1
|
Marble A: Diabetes and cancer. N Engl J
Med. 211:339–349. 1934. View Article : Google Scholar
|
|
2
|
Simon D: I.15 Diabetes and cancer.
Diabetes Res Clin Pract. 103:S52014. View Article : Google Scholar
|
|
3
|
Pandey A, Forte V, Abdallah M, Alickaj A,
Mahmud S, Asad S and McFarlane SI: Diabetes mellitus and the risk
of cancer. Minerva Endocrinol. 36:187–209. 2011.PubMed/NCBI
|
|
4
|
Lee MS, Hsu CC, Wahlqvist ML, Tsai HN,
Chang YH and Huang YC: Type 2 diabetes increases and metformin
reduces total, colorectal, liver and pancreatic cancer incidences
in Taiwanese: A representative population prospective cohort study
of 800,000 individuals. BMC Cancer. 11:202011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meyerhardt JA, Catalano PJ, Haller DG,
Mayer RJ, Macdonald JS, Benson AB III and Fuchs CS: Impact of
diabetes mellitus on outcomes in patients with colon cancer. J Clin
Oncol. 21:433–440. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coughlin SS, Calle EE, Teras LR, Petrelli
J and Thun MJ: Diabetes mellitus as a predictor of cancer mortality
in a large cohort of US adults. Am J Epidemiol. 159:1160–1167.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barone BB, Yeh HC, Snyder CF, Peairs KS,
Stein KB, Derr RL, Wolff AC and Brancati FL: Long-term all-cause
mortality in cancer patients with preexisting diabetes mellitus: A
systematic review and meta-analysis. JAMA. 300:2754–2764. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rao Kondapally, Seshasai S, Kaptoge S,
Thompson A, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup
PH, Mukamal KJ, Gillum RF, et al: Diabetes mellitus, fasting
glucose, and risk of cause-specific death. N Engl J Med.
364:829–841. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu X, Ji J, Sundquist K, Sundquist J and
Hemminki K: The impact of type 2 diabetes mellitus on
cancer-specific survival: A follow-up study in Sweden. Cancer.
118:1353–1361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Currie CJ, Poole CD, Jenkins-Jones S, Gale
EA, Johnson JA and Morgan CL: Mortality after incident cancer in
people with and without type 2 diabetes: Impact of metformin on
survival. Diabetes Care. 35:299–304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vigneri P, Frasca F, Sciacca L, Pandini G
and Vigneri R: Diabetes and cancer. Endocr Relat Cancer.
16:1103–1123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kumar S, Meuter A, Thapa P, Langstraat C,
Giri S, Chien J, Rattan R, Cliby W and Shridhar V: Metformin intake
is associated with better survival in ovarian cancer: A
case-control study. Cancer. 119:555–562. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Emami Riedmaier A, Fisel P, Nies AT,
Schaeffeler E and Schwab M: Metformin and cancer: From the old
medicine cabinet to pharmacological pitfalls and prospects. Trends
Pharmacol Sci. 34:126–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rizos CV and Elisaf MS: Metformin and
cancer. Eur J Pharmacol. 705:96–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bost F, Sahra IB, Le Marchand-Brustel Y
and Tanti JF: Metformin and cancer therapy. Curr Opin Oncol.
24:103–108. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang YX, Hennessy S and Lewis JD: Type 2
diabetes mellitus and the risk of colorectal cancer. Clin
Gastroenterol Hepatol. 3:587–594. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee MY, Lin KD, Hsiao PJ and Shin SJ: The
association of diabetes mellitus with liver, colon, lung, and
prostate cancer is independent of hypertension, hyperlipidemia, and
gout in Taiwanese patients. Metabolism. 61:242–249. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goodwin P: Meta-analysis: Diabetes appears
to increase risk, mortality of breast and colon cancers. Oncol
Times. 35:332013. View Article : Google Scholar
|
|
19
|
Kasper JS and Giovannucci E: A
meta-analysis of diabetes mellitus and the risk of prostate cancer.
Cancer Epidemiol Biomarkers Prev. 15:2056–2062. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gong Z, Neuhouser ML, Goodman PJ, Albanes
D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM
and Kristal AR: Obesity, diabetes, and risk of prostate cancer:
Results from the prostate cancer prevention trial. Cancer Epidemiol
Biomarkers Prev. 15:1977–1983. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Calton BA, Chang SC, Wright ME, Kipnis V,
Lawson K, Thompson FE, Subar AF, Mouw T, Campbell DS, Hurwitz P, et
al: History of diabetes mellitus and subsequent prostate cancer
risk in the NIH-AARP Diet and Health Study. Cancer Causes Control.
18:493–503. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gudmundsson J, Sulem P, Steinthorsdottir
V, Bergthorsson JT, Thorleifsson G, Manolescu A, Rafnar T,
Gudbjartsson D, Agnarsson BA, Baker A, et al: Two variants on
chromosome 17 confer prostate cancer risk, and the one in TCF2
protects against type 2 diabetes. Nat Genet. 39:977–983. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Frayling TM, Colhoun H and Florez JC: A
genetic link between type 2 diabetes and prostate cancer.
Diabetologia. 51:1757–1760. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stevens VL, Ahn J, Sun J, Jacobs EJ, Moore
SC, Patel AV, Berndt SI, Albanes D and Hayes RB: HNF1B and JAZF1
genes, diabetes, and prostate cancer risk. Prostate. 70:601–607.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Waters KM, Henderson BE, Stram DO, Wan P,
Kolonel LN and Haiman CA: Association of diabetes with prostate
cancer risk in the multiethnic cohort. Am J Epidemiol. 169:937–945.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Snyder CF, Stein KB, Barone BB, Peairs KS,
Yeh HC, Derr RL, Wolff AC, Carducci MA and Brancati FL: Does
pre-existing diabetes affect prostate cancer prognosis? A
systematic review. Prostate Cancer Prostatic Dis. 13:58–64. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Issa ZA, Zantout MS and Azar ST: Multiple
myeloma and diabetes. ISRN Endocrinol. 2011:8150132011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Castillo JJ, Mull N, Reagan JL, Nemr S and
Mitri J: Increased incidence of non-Hodgkin lymphoma, leukemia, and
myeloma in patients with diabetes mellitus type 2: A meta-analysis
of observational studies. Blood. 119:4845–4850. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Noto H, Tsujimoto T, Sasazuki T and Noda
M: Significantly increased risk of cancer in patients with diabetes
mellitus: A systematic review and meta-analysis. Endocr Pract.
17:616–628. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
El-Serag HB, Hampel H and Javadi F: The
association between diabetes and hepatocellular carcinoma: A
systematic review of epidemiologic evidence. Clin Gastroenterol
Hepatol. 4:369–380. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen
Y, Li G and Wang L: Increased risk of hepatocellular carcinoma in
patients with diabetes mellitus: A systematic review and
meta-analysis of cohort studies. Int J Cancer. 130:1639–1648. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Friberg E, Orsini N, Mantzoros CS and Wolk
A: Diabetes mellitus and risk of endometrial cancer: A
meta-analysis. Diabetologia. 50:1365–1374. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Larsson SC, Orsini N and Wolk A: Diabetes
mellitus and risk of colorectal cancer: A meta-analysis. J Natl
Cancer Inst. 97:1679–1687. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huxley R, Ansary-Moghaddam A, Berrington
de González A, Barzi F and Woodward M: Type-II diabetes and
pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer.
92:2076–2083. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Everhart J and Wright D: Diabetes mellitus
as a risk factor for pancreatic cancer: A meta-analysis. JAMA.
273:1605–1609. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Larsson SC, Mantzoros CS and Wolk A:
Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J
Cancer. 121:856–862. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wolf I, Sadetzki S, Catane R, Karasik A
and Kaufman B: Diabetes mellitus and breast cancer. Lancet Oncol.
6:103–111. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bonovas S, Filioussi K and Tsantes A:
Diabetes mellitus and risk of prostate cancer: A meta-analysis.
Diabetologia. 47:1071–1078. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Larsson SC, Orsini N, Brismar K and Wolk
A: Diabetes mellitus and risk of bladder cancer: A meta-analysis.
Diabetologia. 49:2819–2823. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chao C and Page JH: Type 2 diabetes
mellitus and risk of non-Hodgkin lymphoma: A systematic review and
meta-analysis. Am J Epidemiol. 168:471–480. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mitri J, Castillo J and Pittas AG:
Diabetes and Risk of Non-Hodgkin's Lymphoma A meta-analysis of
observational studies. Diabetes Care. 31:2391–2397. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gallagher EJ and LeRoith D: The
proliferating role of insulin and insulin-like growth factors in
cancer. Trends Endocrinol Metab. 21:610–618. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chowdhury T: Diabetes and cancer. QJM.
103:905–915. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Djiogue S, Nwabo Kamdje AH, Vecchio L,
Kipanyula MJ, Farahna M, Aldebasi Y and Seke Etet PF: Insulin
resistance and cancer: The role of insulin and IGFs. Endocr Relat
Cancer. 20:R1–R17. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Del Barco S, Vazquez-Martin A, Cufi S,
Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B
and Menendez JA: Metformin: Multi-faceted protection against
cancer. Oncotarget. 2:896–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Clayton PE, Banerjee I, Murray PG and
Renehan AG: Growth hormone, the insulin-like growth factor axis,
insulin and cancer risk. Nat Rev Endocrinol. 7:11–24. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012.PubMed/NCBI
|
|
48
|
Cohen DH and LeRoith D: Obesity, type 2
diabetes, and cancer: The insulin and IGF connection. Endocr Relat
Cancer. 19:F27–F45. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Donath MY and Shoelson SE: Type 2 diabetes
as an inflammatory disease. Nat Rev Immunol. 11:98–107. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xie W and Du L: Diabetes is an
inflammatory disease: Evidence from traditional Chinese medicines.
Diabetes Obes Metab. 13:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cosentino F and Assenza GE: Diabetes and
Inflammation. Herz. 29:749–759. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kern PA, Ranganathan S, Li C, Wood L and
Ranganathan G: Adipose tissue tumor necrosis factor and
interleukin-6 expression in human obesity and insulin resistance.
Am J Physiol Endocrinol Metab. 280:E745–751. 2001.PubMed/NCBI
|
|
53
|
Neurath MF and Finotto S: IL-6 signaling
in autoimmunity, chronic inflammation and inflammation-associated
cancer. Cytokine Growth Factor Rev. 22:83–89. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Waters JP, Pober JS and Bradley JR: Tumour
necrosis factor and cancer. J Pathol. 230:241–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Geerlings SE and Hoepelman AI: Immune
dysfunction in patients with diabetes mellitus (DM). FEMS Immunol
Med Microbiol. 26:259–265. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bowker SL, Majumdar SR, Veugelers P and
Johnson JA: Increased cancer-related mortality for patients with
type 2 diabetes who use sulfonylureas or insulin. Diabetes Care.
29:254–258. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Libby G, Donnelly LA, Donnan PT, Alessi
DR, Morris AD and Evans JM: New users of metformin are at low risk
of incident cancer: A cohort study among people with type 2
diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Li D, Yeung SC, Hassan MM, Konopleva M and
Abbruzzese JL: Antidiabetic therapies affect risk of pancreatic
cancer. Gastroenterology. 137:482–488. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Currie CJ, Poole CD and Gale EA: The
influence of glucose-lowering therapies on cancer risk in type 2
diabetes. Diabetologia. 52:1766–1777. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Donadon V, Balbi M, Valent F and Avogaro
A: Glycated hemoglobin and antidiabetic strategies as risk factors
for hepatocellular carcinoma. World J Gastroenterol. 16:3025–3032.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Donadon V, Balbi M, Mas MD, Casarin P and
Zanette G: Metformin and reduced risk of hepatocellular carcinoma
in diabetic patients with chronic liver disease. Liver Int.
30:750–758. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Landman GW, Kleefstra N, van Hateren KJ,
Groenier KH, Gans RO and Bilo HJ: Metformin associated with lower
cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care.
33:322–326. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Decensi A, Puntoni M, Goodwin P, Cazzaniga
M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in
diabetic patients: A systematic review and meta-analysis. Cancer
Prev Res (Phila). 3:1451–1461. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Jiralerspong S, Palla SL, Giordano SH,
Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi
GN and Gonzalez-Angulo AM: Metformin and pathologic complete
responses to neoadjuvant chemotherapy in diabetic patients with
breast cancer. J Clin Oncol. 27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Bodmer M, Meier C, Krähenbühl S, Jick SS
and Meier CR: Long-term metformin use is associated with decreased
risk of breast cancer. Diabetes Care. 33:1304–1308. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Klubo-Gwiezdzinska J, Costello J Jr, Patel
A, Bauer A, Jensen K, Mete M, Burman KD, Wartofsky L and Vasko V:
Treatment with metformin is associated with higher remission rate
in diabetic patients with thyroid cancer. J Clin Endocrinol Metab.
98:3269–3279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Romero IL, McCormick A, McEwen KA, Park S,
Karrison T, Yamada SD, Pannain S and Lengyel E: Relationship of
type II diabetes and metformin use to ovarian cancer progression,
survival, and chemosensitivity. Obstet Gynecol. 119:61–67. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Patel T, Hruby G, Badani K, Abate-Shen C
and McKiernan JM: Clinical outcomes after radical prostatectomy in
diabetic patients treated with metformin. Urology. 76:1240–1244.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Azoulay L, Dell'Aniello S, Gagnon B,
Pollak M and Suissa S: Metformin and the incidence of prostate
cancer in patients with type 2 diabetes. Cancer Epidemiol
Biomarkers Prev. 20:337–344. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wright JL and Stanford JL: Metformin use
and prostate cancer in Caucasian men: Results from a
population-based case-control study. Cancer Causes Control.
20:1617–1622. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
He XX, Tu SM, Lee MH and Yeung SC:
Thiazolidinediones and metformin associated with improved survival
of diabetic prostate cancer patients. Ann Oncol. 22:2640–2645.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Sadeghi N, Abbruzzese JL, Yeung SC, Hassan
M and Li D: Metformin use is associated with better survival of
diabetic patients with pancreatic cancer. Clin Cancer Res.
18:2905–2912. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Noto H, Goto A, Tsujimoto T and Noda M:
Cancer risk in diabetic patients treated with metformin: A
systematic review and meta-analysis. PLoS One. 7:e334112012.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Hosono K, Endo H, Takahashi H, Sugiyama M,
Sakai E, Uchiyama T, Suzuki K, Iida H, Sakamoto Y, Yoneda K, et al:
Metformin suppresses colorectal aberrant crypt foci in a short-term
clinical trial. Cancer Prev Res (Phila). 3:1077–1083. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Freemark M and Bursey D: The effects of
metformin on body mass index and glucose tolerance in obese
adolescents with fasting hyperinsulinemia and a family history of
type 2 diabetes. Pediatrics. 107:E552001. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Pollak M: Insulin and insulin-like growth
factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Goodwin PJ, Pritchard KI, Ennis M, Clemons
M, Graham M and Fantus IG: Insulin-lowering effects of metformin in
women with early breast cancer. Clin Breast Cancer. 8:501–505.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Memmott RM, Mercado JR, Maier CR, Kawabata
S, Fox SD and Dennis PA: Metformin prevents tobacco
carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila).
3:1066–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Algire C, Amrein L, Bazile M, David S,
Zakikhani M and Pollak M: Diet and tumor LKB1 expression interact
to determine sensitivity to anti-neoplastic effects of metformin in
vivo. Oncogene. 30:1174–1182. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Pollak M: Metformin and other biguanides
in oncology: Advancing the research agenda. Cancer Prev Res
(Phila). 3:1060–1065. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Karnevi E, Said K, Andersson R and
Rosendahl AH: Metformin-mediated growth inhibition involves
suppression of the IGF-I receptor signalling pathway in human
pancreatic cancer cells. BMC Cancer. 13:2352013. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Inoki K, Zhu T and Guan KL: TSC2 mediates
cellular energy response to control cell growth and survival. Cell.
115:577–590. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Gwinn DM, Shackelford DB, Egan DF,
Mihaylova MM, Mery A, Vasquez DS, Turk BE and Shaw RJ: AMPK
phosphorylation of raptor mediates a metabolic checkpoint. Mol
Cell. 30:214–226. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Efeyan A and Sabatini DM: mTOR and cancer:
Many loops in one pathway. Curr Opin Cell Biol. 22:169–176. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Dowling RJ, Zakikhani M, Fantus IG, Pollak
M and Sonenberg N: Metformin inhibits mammalian target of
rapamycin-dependent translation initiation in breast cancer cells.
Cancer Res. 67:10804–10812. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Zakikhani M, Dowling RJ, Sonenberg N and
Pollak MN: The effects of adiponectin and metformin on prostate and
colon neoplasia involve activation of AMP-activated protein kinase.
Cancer Prev Res (Phila). 1:369–375. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Gotlieb WH, Saumet J, Beauchamp MC, Gu J,
Lau S, Pollak MN and Bruchim I: In vitro metformin anti-neoplastic
activity in epithelial ovarian cancer. Gynecol Oncol. 110:246–250.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Cantrell LA, Zhou C, Mendivil A, Malloy
KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of
endometrial cancer cell proliferation-implications for a novel
treatment strategy. Gynecol Oncol. 116:92–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Green AS, Chapuis N, Maciel TT, Willems L,
Lambert M, Arnoult C, Boyer O, Bardet V, Park S, Foretz M, et al:
The LKB1/AMPK signaling pathway has tumor suppressor activity in
acute myeloid leukemia through the repression of mTOR-dependent
oncogenic mRNA translation. Blood. 116:4262–4273. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Zheng L, Yang W, Wu F, Wang C, Yu L, Tang
L, Qiu B, Li Y, Guo L, Wu M, et al: Prognostic significance of AMPK
activation and therapeutic effects of metformin in hepatocellular
carcinoma. Clin Cancer Res. 19:5372–5380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Shi WY, Xiao D, Wang L, Dong LH, Yan ZX,
Shen ZX, Chen SJ, Chen Y and Zhao WL: Therapeutic metformin/AMPK
activation blocked lymphoma cell growth via inhibition of mTOR
pathway and induction of autophagy. Cell Death Dis. 3:e2752012.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Ben Sahra I, Regazzetti C, Robert G, et
al: Metformin, independent of AMPK, induces mTOR inhibition and
cell-cycle arrest through REDD1. Cancer Res. 71:4366–4372. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Kalender A, Selvaraj A, Kim SY, Gulati P,
Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, et
al: Metformin, independent of AMPK, inhibits mTORC1 in a rag
GTPase-dependent manner. Cell Metab. 11:390–401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Janjetovic K, Harhaji-Trajkovic L,
Misirkic-Marjanovic M, Vucicevic L, Stevanovic D, Zogovic N,
Sumarac-Dumanovic M, Micic D and Trajkovic V: In vitro and in vivo
anti-melanoma action of metformin. Eur J Pharmacol. 668:373–382.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Yasmeen A, Beauchamp MC, Piura E, Segal E,
Pollak M and Gotlieb WH: Induction of apoptosis by metformin in
epithelial ovarian cancer: Involvement of the Bcl-2 family
proteins. Gynecol Oncol. 121:492–498. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Zi FM, He JS, Li Y, Wu C, Yang L, Yang Y,
Wang LJ, He DH, Zhao Y, Wu WJ, et al: Metformin displays
anti-myeloma activity and synergistic effect with dexamethasone in
in vitro and in vivo xenograft models. Cancer Lett. 356:443–453.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Liang J and Mills GB: AMPK: A contextual
oncogene or tumor suppressor? Cancer Res. 73:2929–2935. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Hardie DG: The LKB1-AMPK pathway-friend or
foe in cancer? Cancer Cell. 23:131–132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Park HU, Suy S, Danner M, Dailey V, Zhang
Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, et al:
AMP-activated protein kinase promotes human prostate cancer cell
growth and survival. Mol Cancer Ther. 8:733–741. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Baumann P, Mandl-Weber S, Emmerich B,
Straka C and Schmidmaier R: Inhibition of adenosine
monophosphate-activated protein kinase induces apoptosis in
multiple myeloma cells. Anticancer Drugs. 18:405–410. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Shackelford DB, Abt E, Gerken L, Vasquez
DS, Seki A, Leblanc M, Wei L, Fishbein MC, Czernin J, Mischel PS
and Shaw RJ: LKB1 inactivation dictates therapeutic response of
non-small cell lung cancer to the metabolism drug phenformin.
Cancer Cell. 23:143–158. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Liu X, Chhipa RR, Pooya S, Wortman M,
Yachyshin S, Chow LM, Kumar A, Zhou X, Sun Y, Quinn B, et al:
Discrete mechanisms of mTOR and cell cycle regulation by AMPK
agonists independent of AMPK. Proc Natl Acad Sci USA. 111:pp.
E435–E444. 2014; View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Garcia A and Tisman G: Metformin, B(12),
and enhanced breast cancer response to chemotherapy. J Clin Oncol.
28:e19–e20. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Ben Sahra I, Laurent K, Giuliano S,
Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y,
Giorgetti-Peraldi S, Cormont M, Bertolotto C, et al: Targeting
cancer cell metabolism: The combination of metformin and
2-deoxyglucose induces p53-dependent apoptosis in prostate cancer
cells. Cancer Res. 70:2465–2475. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Ben Sahra I, Tanti JF and Bost F: The
combination of metformin and 2 deoxyglucose inhibits autophagy and
induces AMPK-dependent apoptosis in prostate cancer cells.
Autophagy. 6:670–671. 2010. View Article : Google Scholar
|
|
108
|
Colquhoun AJ, Venier NA, Vandersluis AD,
Besla R, Sugar LM, Kiss A, Fleshner NE, Pollak M, Klotz LH and
Venkateswaran V: Metformin enhances the antiproliferative and
apoptotic effect of bicalutamide in prostate cancer. Prostate
Cancer Prostatic Dis. 15:346–352. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Rocha GZ, Dias MM, Ropelle ER,
Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ and Carvalheira JB:
Metformin amplifies chemotherapy-induced AMPK activation and
antitumoral growth. Clin Cancer Res. 17:3993–4005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Rattan R, Graham RP, Maguire JL, Giri S
and Shridhar V: Metformin suppresses ovarian cancer growth and
metastasis with enhancement of cisplatin cytotoxicity in vivo.
Neoplasia. 13:483–491. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Iliopoulos D, Hirsch HA and Struhl K:
Metformin decreases the dose of chemotherapy for prolonging tumor
remission in mouse xenografts involving multiple cancer cell types.
Cancer Res. 71:3196–3201. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Hanna RK, Zhou C, Malloy KM, Sun L, Zhong
Y, Gehrig PA and Bae-Jump VL: Metformin potentiates the effects of
paclitaxel in endometrial cancer cells through inhibition of cell
proliferation and modulation of the mTOR pathway. Gynecol Oncol.
125:458–469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Janjetovic K, Vucicevic L, Misirkic M,
Vilimanovich U, Tovilovic G, Zogovic N, Nikolic Z, Jovanovic S,
Bumbasirevic V, Trajkovic V and Harhaji-Trajkovic L: Metformin
reduces cisplatin-mediated apoptotic death of cancer cells through
AMPK-independent activation of Akt. Eur J Pharmacol. 651:41–50.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Donnenberg VS and Donnenberg AD: Multiple
drug resistance in cancer revisited: The cancer stem cell
hypothesis. J Clin Pharmacol. 45:872–877. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Eyler CE and Rich JN: Survival of the
fittest: Cancer stem cells in therapeutic resistance and
angiogenesis. J Clin Oncol. 26:2839–2845. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Clevers H: The cancer stem cell: Premises,
promises and challenges. Nat Med. 17:313–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Hirsch HA, Iliopoulos D, Tsichlis PN and
Struhl K: Metformin selectively targets cancer stem cells, and acts
together with chemotherapy to block tumor growth and prolong
remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Cufi S, Corominas-Faja B, Vazquez-Martin
A, Oliveras-Ferraros C, Dorca J, Bosch-Barrera J, Martin-Castillo B
and Menendez JA: Metformin-induced preferential killing of breast
cancer initiating CD44+CD24-/low cells is sufficient to overcome
primary resistance to trastuzumab in HER2+ human breast cancer
xenografts. Oncotarget. 3:395–398. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Song CW, Lee H, Dings RP, Williams B,
Powers J, Santos TD, Choi BH and Park HJ: Metformin kills and
radiosensitizes cancer cells and preferentially kills cancer stem
cells. Sci Rep. 2:3622012. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Shank JJ, Yang K, Ghannam J, Cabrera L,
Johnston CJ, Reynolds RK and Buckanovich RJ: Metformin targets
ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol.
127:390–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Bao B, Wang Z, Ali S, Ahmad A, Azmi AS,
Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S and Sarkar FH:
Metformin inhibits cell proliferation, migration and invasion by
attenuating CSC function mediated by deregulating miRNAs in
pancreatic cancer cells. Cancer Prev Res (Phila). 5:355–364. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Mayer MJ, Klotz LH and Venkateswaran V:
Metformin and prostate cancer stem cells: A novel therapeutic
target. Prostate Cancer Prostatic Dis. 18:303–309. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Di Francesco AM, Toesca A, Cenciarelli C,
Giordano A, Gasbarrini A and Puglisi MA: Metabolic modification in
gastrointestinal cancer stem cells: Characteristics and therapeutic
approaches. J Cell Physiol. 231:2081–2087. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Florio T: Antitumoral effects of metformin
on cancer stem cells. Ann d'Endocrinologie. 76:2962015. View Article : Google Scholar
|
|
125
|
Rattan R, Ali Fehmi R and Munkarah A:
Metformin: An emerging new therapeutic option for targeting cancer
stem cells and metastasis. J Oncol. 2012:9281272012. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Bednar F and Simeone DM: Metformin and
cancer stem cells: Old drug, new targets. Cancer Prev Res (Phila).
5:351–354. 2012. View Article : Google Scholar : PubMed/NCBI
|
